Mediwound Ltd is a biotechnology company focused on developing and commercializing innovative therapies for patients with severe and chronic wounds. The company specializes in advanced wound care products and therapies, including bioactive agents that aim to promote healing and improve the quality of life for patients suffering from wounds that are difficult to treat. MediWound's commitment to research and development drives its efforts to provide effective solutions in the wound care sector, addressing both acute and chronic wound challenges in healthcare settings. Read More
MediWound (NASDAQ:MDWD) reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance its EscharEx and NexoBrid programs.
On the company’s earnings call, Chief Executive Officer Ofer G
MediWound's Q3 2025 results show revenue miss but a smaller-than-expected loss. The company advances its EscharEx pipeline and expands NexoBrid manufacturing.
